ALERTS, CHARTS, & HOT STOCKS

[budfoxfun]

$NBIO now with the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates - particularly early-stage pipelines with recent identifiable traction targeting large end markets.

One such example is Nascent Biotech Inc. (OTCMKTS:NBIO), an emerging player in the $4 billion oncology drug development space.

NBIO is certainly early-stage: its flagship drug is just heading toward Phase 2 clinical research, right in the sweet spot for dealmaking as a potential acquisition target as deals pick up pace this cycle. https://www.marketwatch.com/press-release/fishing-for-bargains-nascent-biotech-otcmktsnbio-ripe-for-acquisition-2022-11-30?reflink=mw_share_twitter